Abbott Secures FDA Authorization for Libre Duo 10 Day, a Dual Glucose-Ketone Sensing Technology

Shots: FDA has approved Libre Duo 10 Day, a dual glucose-ketone sensing biowearable, to provide real-time glucose monitoring while continuously detecting rising ketones for diabetic ketoacidosis (DKA) emergency, with launch expected later this year Libre Duo 10 Day met FDA standards for both integrated continuous glucose monitoring (iCGM) & the new integrated continuous glucose & ketone monitoring (iCGK) standard, offering ~10 days of wear & is intended for people with diabetes aged 2 yrs. & older Abbott is partnering with leading pump makers to integrate Libre Duo 10 Day with automated insulin delivery systems, incl. Beta Bionics’ iLet & Sequel Med Tech’s twiist by year-end, Insulet & Tandem in 2027, plus an exclusive Abbott-MiniMed integration expected in 2027 Ref: PRnewswire  |  Image: Abbott   |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Abbott Secures FDA Authorization for Libre Duo 10 Day, a Dual Glucose-Ketone Sensing Technology appeared first on PharmaShots.